paid $25,000, or approximately $0.011 per share, to cover certain offering costs in consideration for 2,156,250 founder shares. On May 10, 2022, our Sponsor surrendered 287,500 founder
shares, for no consideration, resulting in our Sponsor and directors continuing to hold 1,868,750 founder shares. On August 26, 2022, our Sponsor transferred 25,000 founder shares to each of Rahul Mewawalla and Stephen Markscheid, each of which
are members of our Board. The awards will vest simultaneously with the closing of an initial business combination, provided the director has continuously served on Board through the closing of such initial business combination.
Our IPO Registration Statement was declared effective on March 16, 2023. On March 22, 2023, we consummated the IPO of 5,200,000
units. Each unit sold in the IPO consisted of one share of Class A common stock and one public warrant exercisable into one share of Class A common stock at an exercise price of $11.50 per share. The units were sold at an offering price of
$10.00 per unit, generating total gross proceeds of $54,210,000, and incurring offering costs (including the partial exercise of the underwriters over-allotment option on March 17, 2023) of approximately $4.0 million, consisting of
approximately $0.8 million of underwriting commissions, approximately $1.9 million of deferred underwriting commissions that will be paid solely in the event that we complete an initial business combination, approximately $0.3 million
representing the fair value of the 54,210 shares of Class A common stock issued to the underwriter of the IPO, and approximately $1.0 million of other offering costs.
In connection with the consummation of the IPO, on March 16, 2023, our Sponsor forfeited an aggregate of 373,750 founder shares for no
consideration, resulting in our Sponsor and directors holding an aggregate of 1,495,000 founder shares, of which up to 195,000 founders shares were subject to forfeiture to the extent the over-allotment option was not exercised in full by the
underwriter prior to its expiration date on April 30, 2023. On March 17, 2023, the underwriters partially exercised their over-allotment option and purchased 221,000 additional units. Upon the partial exercise the over-allotment option by
the underwriters, the forfeiture lapsed for 55,250 founder shares. Following the expiration of the underwriters remaining over-allotment option on April 30, 2023, the remaining 139,750 founder shares were forfeited, resulting in our
Sponsor and directors holding an aggregate of 1,355,250 founder shares.
Simultaneously with the closing of the IPO, we consummated the
private placement (Private Placement) of 3,576,900 private warrants (the private warrants), which were purchased by our Sponsor, at a price of $1.00 per private warrant, generating gross proceeds to us of approximately
$3.58 million. Upon the closing of the IPO and the Private Placement (including the additional units sold in connection with the partial exercise of the underwriters over-allotment option), $55,836,300 ($10.30 per public unit) of the net
proceeds of the sale of the units in the IPO and the Private Placement were placed into the Trust Account.
Pursuant to the terms of our
Amended Certificate, we were initially granted 12 months to complete an initial business combination with a target company, with the option, but not the obligation, to extend the period of time to consummate an initial business combination up to two
times by an additional three-month period each time (for a total of up to 18 months to complete a business combination). Pursuant to the terms of our Amended Certificate and the Trust Agreement entered into between us and Continental, in order to
extend the time available for us to consummate our initial business combination, our Sponsor, upon at least five days advance notice prior to the applicable deadline, must deposit into the Trust Account for each three-month extension an amount equal
to $0.10 per public share on or prior to the date of the applicable deadline. On March 19, 2024, we exercised the first extension to extend the date by which we must consummate an initial business combination transaction from March 22,
2024 to June 22, 2024 (i.e., for a period of time ending 15 months after the consummation of the initial public offering) and our Sponsor deposited the extension funds into the Trust Account.
The Extension Amendment Proposal
We are proposing to amend our Amended Certificate to extend the date by which we must consummate an initial business combination from the
Current Termination Date (June 22, 2024) (assuming we do not decide to
23